IVG
29.1.2020 10:02:13 CET | Business Wire | Press release
Two massive wins for IVG (I Vape Great) is the reason for their celebration. Over the last 4 years, IVG has sold 14 million bottles of e-liquid, the global e-liquid firm based in Preston has been selected to sell their products in 41 airport terminals and in 22 airports across the UK. After going head to head with some of the biggest names in the vape industry IVG has also been crowned UK’s Best Brand of 2019 at the Ecigclick Awards , which saw a record amount of voters.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200129005020/en/
“We are delighted to have won this award and to have our products entering airports across the United Kingdom. We think this is a fantastic opportunity, not only for vapers but also for smokers wanting to switch to vaping worldwide ” – Ahsan Bawa CEO of IVG Premium E-Liquids.
Which IVG Products Will Be Available in The Airports?
By the end of January, we can expect to see a new easy to carry around travel pack with four of IVG’s world-renowned flavours and one new flavour exclusively available in airports, Bubblegum, Summer Blaze, Blue Raspberry, Silver Tobacco, and Super Ice Menthol. All the e-liquids will be available in 50PG/50VG 6mg and 12mg.
How Does This Benefit FMCG & Retail Sectors?
Opportunity - Vaping is tipped to be a £2.5bn market by 2025, with 80% of vapers looking to quit smoking. Threat - without an alternative, in 10 years, convenience retailers will have lost £107m every month.
IVG entering airports will raise awareness of Vaping, the opportunity for retailers to stock vaping products or improve on their selection of existing products and having a strong vaping brand as IVG will improve the chances of surviving the loss of sales from people switching to vaping from smoking.
What Does This Mean for The Vape Industry?
IVG is paving the way for vape brands being readily available in the FMCG & Retail sectors and as one of the worlds most recognised brands, IVG predicts that this will be a huge success which the whole vape industry can benefit from.
Airports Where You Can Find IVG E-Liquids
London Gatwick, London Heathrow, London Stanstead, Manchester, Bournemouth, Exeter, Eurotunnel, Jersey, Belfast, Prestwick, Glasgow, Aberdeen, Edinburgh, Newcastle, Birmingham, East Midlands, Bristol, Southampton, Liverpool, Leeds, Humberside and Doncaster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005020/en/
Social Media:
https://www.facebook.com/ivgeliquids
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom